At least one minor positive is that the performance shares are unlikely to vest and convert to shares.
Class A requires a 20 day VWAP of $2.00 per share and US$6.6m in revenue for CY17 (no chance)
Class B requires a 20 day VWAP of $2.50 per share and US$6.6m in revenue for CY17 (no chance)
Class C already lapsed
Class D requires US$20m for CY17 (unlikely)
News: M7T Mach7 Technologies to divest its 3D medical operations, page-5
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add M7T (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.5¢ |
Change
-0.015(2.46%) |
Mkt cap ! $143.5M | |||
| Open | High | Low | Value | Volume |
| 61.0¢ | 61.0¢ | 59.0¢ | $105.1K | 177.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2091 | 59.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 61.0¢ | 20659 | 2 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| M7T (ASX) Chart |